Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.
| Autor: | Sadowski, Claire, Belknap, Robert, Holland, David P, Moro, Ruth N, Chen, Michael P, Wright, Alicia, Millet, Joan Pau, Caylà, Joan A, Scott, Nigel A, Borisov, Andrey, Gandhi, Neel R |
|---|---|
| Předmět: |
STATISTICS
COMBINATION drug therapy CONFIDENCE intervals RIFAXIMIN MULTIPLE regression analysis AGE distribution LATENT tuberculosis ISONIAZID RISK assessment SEX distribution DESCRIPTIVE statistics DRUGS RESEARCH funding RIFAMPIN STATISTICAL models DRUG side effects ODDS ratio PATIENT compliance SYMPTOMS |
| Zdroj: | Clinical Infectious Diseases; 6/15/2023, Vol. 76 Issue 12, p2090-2097, 8p |
| Abstrakt: | Background Three months of weekly rifapentine plus isoniazid (3HP) therapy for latent tuberculosis infection (LTBI) is recommended worldwide. The development of symptoms and systemic drug reactions (SDRs) on 3HP have not been fully characterized. We aimed to determine the patterns of symptom development and identify SDRs and associated factors in patients taking 3HP. Methods We analyzed symptoms data in participants receiving 3HP in the Tuberculosis Trials Consortium's iAdhere study (Study 33). We examined the patterns of symptom reporting across participants from baseline and 4 monthly visits. Bivariate analyses and multivariable regression models were used to identify factors associated with SDRs. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated. Results Among 1002 participants receiving 3HP, 768 (77%) reported at least 1 symptom; 97% of these symptoms were grade 1 (79%) or grade 2 (18%). Most symptoms developed in the first month and resolved. A total of 111 (11%) participants had symptoms that met criteria for SDRs; however, 53 (48%) of these participants completed therapy. Factors associated with SDRs and discontinuation included female sex (RR: 2.05; 95% CI: 1.19–3.54), age ≥45 years (RR: 1.99; 95% CI: 1.19–3.31), and use of concomitant medications (RR: 2.26; 95% CI: 1.15–4.42). Conclusions Although most patients receiving 3HP reported symptoms, most were mild, occurred early, and resolved without stopping treatment. Among patients experiencing SDRs, nearly half were able to complete therapy. Patient and provider education should focus on differentiating severe reactions where 3HP should be stopped from minor symptoms that will resolve. Clinical Trials Registration. NCT01582711. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|